FMP

FMP

Enter

PCVX - Vaxcyte, Inc.

photo-url-https://images.financialmodelingprep.com/symbol/PCVX.png

Vaxcyte, Inc.

PCVX

NASDAQ

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

74.37 USD

1.35 (1.82%)

Free Cash Flow

Year

2020

2021

2022

2023

2024

2025

2026

2027

2028

2029

Revenue

2.76B

1.76B

1.57B

1.39B

1.38B

1.18B

1B

853.43M

727.07M

619.42M

Revenue %

-

-36.34

-10.71

-11.56

-0.61

-14.81

-14.81

-14.81

-14.81

Operating Cash Flow

134.53M

19.82M

-133.01M

76.93M

62.37M

17.84M

15.2M

12.95M

11.03M

9.4M

Operating Cash Flow %

4.87

1.13

-8.47

5.54

4.52

1.52

1.52

1.52

1.52

Cap Ex

-33.71M

-36.27M

-27.65M

-23.55M

-23.6M

-19.87M

-16.93M

-14.42M

-12.29M

-10.47M

Cap Ex %

-1.22

-2.06

-1.76

-1.7

-1.71

-1.69

-1.69

-1.69

-1.69

Free Cash Flow

100.82M

-16.45M

-160.66M

53.38M

38.77M

-2.03M

-1.73M

-1.47M

-1.26M

-1.07M

Weighted Average Cost Of Capital

Price

1.91

Beta

Diluted Shares Outstanding

32.56M

Costof Debt

10.51

Tax Rate

After Tax Cost Of Debt

10.51

Risk Free Rate

Market Risk Premium

Cost Of Equity

Total Debt

366.79M

Total Equity

62.19M

Total Capital

428.98M

Debt Weighting

85.5

Equity Weighting

14.5

Wacc

9.25

Build Up Free Cash Flow

Year

2020

2021

2022

2023

2024

2025

2026

2027

2028

2029

Revenue

2.76B

1.76B

1.57B

1.39B

1.38B

1.18B

1B

853.43M

727.07M

619.42M

Operating Cash Flow

134.53M

19.82M

-133.01M

76.93M

62.37M

17.84M

15.2M

12.95M

11.03M

9.4M

Cap Ex

-33.71M

-36.27M

-27.65M

-23.55M

-23.6M

-19.87M

-16.93M

-14.42M

-12.29M

-10.47M

Free Cash Flow

100.82M

-16.45M

-160.66M

53.38M

38.77M

-2.03M

-1.73M

-1.47M

-1.26M

-1.07M

Wacc

9.25

9.25

9.25

9.25

9.25

Pv Lfcf

-1.86M

-1.45M

-1.13M

-881.81k

-687.64k

Sum Pv Lfcf

-6.01M

Terminal Value

Growth In Perpetuity Method

Long Term Growth Rate

Wacc

9.25

Free Cash Flow T1

-1.09M

Terminal Value

-15.06M

Present Terminal Value

-9.67M

Intrinsic Value

Enterprise Value

-15.68M

Net Debt

325.52M

Equity Value

-341.2M

Diluted Shares Outstanding

32.56M

Equity Value Per Share

-10.48

Projected DCF

-10.48 1.182%

DCF Levered

Download Excel

FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedin
2017-2024 © Financial Modeling Prep